Literature DB >> 9808561

Association between ligand-induced conformational changes of integrin IIbbeta3 and IIbbeta3-mediated intracellular Ca2+ signaling.

S Honda1, Y Tomiyama, T Aoki, M Shiraga, Y Kurata, J Seki, Y Matsuzawa.   

Abstract

Platelet IIbbeta3 is a prototypic integrin and plays a critical role in platelet aggregation. Occupancy of IIbbeta3 with multivalent RGD ligands, such as fibrinogen, induces both expression of ligand-induced binding sites (LIBS) and IIbbeta3 clustering, which are thought to be necessary for outside-in signaling. However, the association between LIBS expression and outside-in signaling remains elusive. In this study, we used various IIbbeta3-specific peptidomimetic compounds as a monovalent ligand instead of fibrinogen and examined the association between LIBS expression and outside-in signaling such as IIbbeta3-mediated intracellular Ca2+ signaling. Using a set of monoclonal antibodies (MoAbs) against LIBS, we showed that antagonists can be divided into two groups. In group I, antagonists can induce LIBS on both IIb and beta3 subunits. In group II, antagonists can induce LIBS on the IIb subunit, but not on the beta3 subunit. Inhibition studies suggested that group I and group II antagonists interact with distinct but mutually exclusive sites on IIbbeta3. Neither group I nor group II antagonist increased intracellular Ca2+ concentrations ([Ca2+]i) in nonactivated platelets. All antagonists at nanomolar concentrations abolished the increase in [Ca2+]i in 0.03 U/mL thrombin-stimulated platelets, which is dependent on both fibrinogen-binding to IIbbeta3 and platelet-aggregation. However, only group I antagonists at higher concentrations dose-dependently augmented the [Ca2+]i increase, which is due to aggregation-independent thromboxane A2 production. This increase in [Ca2+]i was not observed in thrombasthenic platelets, which express no detectable IIbbeta3. Thus, only the group I antagonists, albeit a monovalent ligand, can initiate IIbbeta3-mediated intracellular Ca2+ signaling in the presence of thrombin stimulation. Our findings strongly suggest the association between beta3 LIBS expression and IIbbeta3-mediated intracellular Ca2+ signaling in platelets.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9808561

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

Review 1.  Comparative pharmacology of GP IIb/IIIa antagonists.

Authors:  Karsten Schrör; Artur-Aron Weber
Journal:  J Thromb Thrombolysis       Date:  2003-04       Impact factor: 2.300

Review 2.  Integrins as therapeutic targets: lessons and opportunities.

Authors:  Dermot Cox; Marian Brennan; Niamh Moran
Journal:  Nat Rev Drug Discov       Date:  2010-10       Impact factor: 84.694

3.  Mapping early conformational changes in alphaIIb and beta3 during biogenesis reveals a potential mechanism for alphaIIbbeta3 adopting its bent conformation.

Authors:  W Beau Mitchell; Jihong Li; Marta Murcia; Nathalie Valentin; Peter J Newman; Barry S Coller
Journal:  Blood       Date:  2007-01-05       Impact factor: 22.113

4.  Structure-guided design of a high-affinity platelet integrin αIIbβ3 receptor antagonist that disrupts Mg²⁺ binding to the MIDAS.

Authors:  Jieqing Zhu; Won-Seok Choi; Joshua G McCoy; Ana Negri; Jianghai Zhu; Sarasija Naini; Jihong Li; Min Shen; Wenwei Huang; Daniel Bougie; Mark Rasmussen; Richard Aster; Craig J Thomas; Marta Filizola; Timothy A Springer; Barry S Coller
Journal:  Sci Transl Med       Date:  2012-03-14       Impact factor: 17.956

5.  RUC-4: a novel αIIbβ3 antagonist for prehospital therapy of myocardial infarction.

Authors:  Jihong Li; Spandana Vootukuri; Yi Shang; Ana Negri; Jian-Kang Jiang; Mark Nedelman; Thomas G Diacovo; Marta Filizola; Craig J Thomas; Barry S Coller
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-08-21       Impact factor: 8.311

Review 6.  Glycoprotein IIb/IIIa inhibitor-induced thrombocytopenia: diagnosis and treatment.

Authors:  S M Said; J Hahn; E Schleyer; M Müller; G M Fiedler; M Buerke; R Prondzinsky
Journal:  Clin Res Cardiol       Date:  2006-12-08       Impact factor: 5.460

Review 7.  αIIbβ3: structure and function.

Authors:  B S Coller
Journal:  J Thromb Haemost       Date:  2015-06       Impact factor: 5.824

8.  Group IVA cytosolic phospholipase A2 (cPLA2alpha) and integrin alphaIIbbeta3 reinforce each other's functions during alphaIIbbeta3 signaling in platelets.

Authors:  Nicolas Prévost; John V Mitsios; Hisashi Kato; John E Burke; Edward A Dennis; Takao Shimizu; Sanford J Shattil
Journal:  Blood       Date:  2008-10-07       Impact factor: 22.113

Review 9.  Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management.

Authors:  R H Aster; B R Curtis; J G McFarland; D W Bougie
Journal:  J Thromb Haemost       Date:  2009-04-02       Impact factor: 5.824

10.  Application of high-throughput screening to identify a novel alphaIIb-specific small- molecule inhibitor of alphaIIbbeta3-mediated platelet interaction with fibrinogen.

Authors:  Robert Blue; Marta Murcia; Charles Karan; Markéta Jirousková; Barry S Coller
Journal:  Blood       Date:  2007-10-31       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.